Medical research has determined the cause of the condition to be a loss of function of specialized cells in the brain stem which stimulate the production of the neurotransmitter, dopamine.
Parkinson’s disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology as the gold standard to establish the definitive diagnosis. We propose that, given biomarker advances enabling accurate detection of pathological α-synuclein (ie, misfolded and aggregated) in CSF using the seed amplification assay, it is time to redefine Parkinson’s disease and dementia with Lewy bodies as neuronal α-synuclein disease rather than as clinical syndromes. This major shift from a clinical to a biological definition of Parkinson’s disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal α-synuclein (n-αsyn) in human beings during life. Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome <
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00405-2/fulltext
10 Fascinating Facts About Parkinson’s Disease You Probably Didn’t Know – David Perlmutter M.D.
Parkinson’s disease in traditional Chinese medicine
10 Fascinating Facts About Parkinson’s Disease You Probably Didn’t Know
Multiple System Atrophy Clinical Presentation: History and Physical Examination
PD is sad to open doors stimulatee creativity. At worst it will be an aggravation on the way to death.